What is the IC50 of doxorubicin in MCF7?
Best insight from top research papers
The IC50 of doxorubicin in MCF7 cells was found to be 3.73 µM .
Answers from top 4 papers
More filters
| Papers (4) | Insight |
|---|---|
30 Mar 2019 | The IC50 of doxorubicin in parental MCF-7 cells is 0.68 µg/ml. |
7 Citations | The IC50 of doxorubicin in MCF-7 is 0.01 μM. |
31 Mar 2023 | The IC50 value of doxorubicin in MCF-7 cells is 3.73 µM. |
Open access•Journal Article 1 Citations | The IC50 of doxorubicin in MCF-7 cells is 5.074μg/mL. |
Related Questions
What is the ic50 of doxrubicin against cancer cell lines?5 answersThe IC50 values of doxorubicin against various cancer cell lines were determined in different studies. In one study, the IC50 values for A549, HepG2, HT29, and K562 cell lines were assessed, showing varying responses to doxorubicin treatment. Another study compared the IC50 values of doxorubicin with a newly developed analog, DA-125, across 20 human cancer cell lines, demonstrating that DA-125 exhibited lower IC50 values than doxorubicin in most cases, particularly in hepatocellular and gastrointestinal cancer cells. Additionally, the efficacy of doxorubicin was compared with daunorubicin (DnR) in various tumor cell types, showing comparable activity between the two anthracyclines, with some solid tumor cell types being more responsive to DnR than doxorubicin.
How does a cytotoxicity assay determine the EC50?5 answersA cytotoxicity assay determines the EC50 by measuring the percentage of living cells after exposure to a compound or substance. The assay evaluates the cytotoxic effect of the compound on cells and calculates the concentration at which 50% of the cells are affected. Different methods can be used for cytotoxicity assays, such as the tetrazolium colorimetric assay (MTT)or an electrochemical bioactivity sensor system. The MTT assay measures cell viability by assessing the reduction of tetrazolium salts by living cells. The EC50 is determined by plotting the concentration of the compound against the percentage of living cells and finding the concentration at which 50% of the cells are viable. The electrochemical bioactivity sensor system measures the reduction of mediator molecules by mammalian cells, and the EC50 is determined by observing the reduction in current signal when a toxic substance is added to the cells.
Doxorubicin drug doses used on MG63 cell line4 answersDoxorubicin drug doses used on MG63 cell line were not explicitly mentioned in the abstracts provided.
What is the ic 50 values of resveratrol on mtt assay for anticancer activity against HEK293 cell lines?5 answersResveratrol's IC50 values on MTT assay for anticancer activity against HEK293 cell lines were not mentioned in the provided abstracts.
Doxorubicin dose mg per kg body weight3 answersDoxorubicin dose is typically given in mg per kg of body weight. High-dose doxorubicin administration at doses ≥150 mg/m2 has been shown to be safe and effective for patients with breast cancer. In the study by Aabo et al., a variety of solid tumor patients received aclarubicin at dose levels of 80-140 mg/m2. For daptomycin, limited clinical data is available for doses greater than 6 mg/kg. In the case of acetaminophen overdose in young children, the recommended threshold dose for interventions is 150 mg/kg. The authors of the study by Rey et al. note that the dosage of 30 mg/kg of oltipraz used in their study was likely insufficient.
How to load doxorubicin in liposomes?3 answersDoxorubicin can be loaded into liposomes using different methods. One method is remote loading, where doxorubicin is encapsulated in liposomes using an ammonium sulfate gradient method. Another method is co-encapsulation, where doxorubicin is co-encapsulated with other drugs in liposomes. Additionally, liposomes can be drawn into nanotubes, forming a unique structure called DoxL-PAuNT, which allows for efficient release of doxorubicin. Another approach is to load doxorubicin-carrying liposomes onto the surfaces of macrophages, utilizing their active tumor-targeting capability. These different methods provide options for loading doxorubicin into liposomes, allowing for controlled and targeted delivery of the drug to tumor sites.